Sun Pharma Q4 FY25 Revenue Rises 8.5% to ₹12,816 Crore

23 May 2025 , 12:07 PM

Sun Pharmaceutical Industries Ltd has released its Q4 results for the quarter and the full financial year ended 31st March, 2025, with strong performance in key markets.

The company’s consolidated gross sales for the quarter ended March 2025 was at ₹12,815.6 crore, a 8.5% year-on-year growth, led by strong traction in India and global specialty business.

During the quarter, India formulation sales rose by 13.6% to ₹4,213 crore on the back of a strong prescription and an increasing portfolio of products in chronic therapies.

The company’s R&D investment was at ₹816.6 crore, which highlights its continued focus on innovation and robust new product pipeline. Operating performance was robust, with EBITDA climbing 22.4% to ₹3,716.1 crore. EBITDA margin for the quarter was strong 28.7% mechanism of effective cost control and product mix.

Net profit for the quarter came in at ₹2,889.1 crore, up 4.8% from the year earlier, adjusted for exceptional items. However, reported net profit came in at ₹2,149.9 crore as against ₹2,654.6 crore in Q4 FY24 because of one-time charges.

For the full year FY25, Sun Pharma recorded gross sales of ₹52,041.2 crore, a 9% increase over FY24 driven more by consistent performance across all regions.

India formulation sales for the year were ₹16,923 crore, higher by 13.7%, emerged as the key growth driver. The US segment achieved full-year sales of $1.921bn, an increase of 3.6%, benefiting from a consistent platform of products.

Global specialty winds generated $1.216 billion of net sales in FY2017, up a solid 17.1% year-on-year. This vertical contributed around 20% to the company’s consolidated revenues in FY25. There were $1.114 billion of sales for FY25 from emerging markets (growth of 7%) and $847 million for the Rest of World (up 4.5%).

Annualised EBITDA was at ₹15,271.7 crore, up 17.3%. EBITDA margin expansion to 29%, was a slide on the operational efficiency. Net profit for the year was ₹11,984.4 crore, an increase 19%. The reported net profit was at ₹10,929 crore as against ₹9,576.4 crore in FY24.

The Board recommended a final dividend of ₹5.50 per share for FY25. The total dividend for the year, including ₹10.50 interim dividend already paid, will be ₹16 per share against ₹13.50 in the previous year.

The company’s chairman and MD Dilip Shanghvi said that the company executed well and delivered strong performance with an enhanced market share in India and good growth in its global specialty operations. Near-term pipeline for specialty medicines is encouraging & new products like Leqselvi & Unloxcyn will further improve patient outcomes, Choksi said.